Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Advanced (metastatic or locally advanced) serous epithelial ovarian, serous fallopian tubal or serous primary peritoneal cancer or advanced clear cell or papillary renal cell carcinoma who have received or are intolerant to all therapy known to confer clinical benefit for their disease, as determined by the investigator.
Tumor sample is available for retrospective CDH6 expression testing
Eastern Cooperative Oncology Group (ECOG) Performance status ≤2
You may not be if
Patient has central nervous system metastatic involvement. Patients with previously treated CNS metastases are also excluded.
Patient with any active or chronic corneal disorders
Patients with monocular vision or have media opacities or any other condition that precludes monitoring of the retina or fundus.
Patients with a history of serious allergic reactions
Patients with QTcF \>470 msec at screening ECG or congenital long QT syndrome
Any prior history of treatment with maytansine (DM1 or DM4)-based ADC
Patient have received anti-cancer therapies within the following time frames prior to the first dose of study treatment:
* Conventional cytotoxic chemotherapy: ≤4 weeks (≤ 6 weeks for nitrosoureas and mitomycin-C)
* Biologic therapy (e.g., antibodies): ≤4 weeks
* Non-cytotoxic small molecule therapeutics: ≤5 half-lives or ≤2 weeks (whichever is longer)
* Other investigational agents: ≤4 weeks
* Radiation therapy (except for localized radiotherapy for analgesic purpose or for lytic lesions at risk of fracture): ≤4 weeks
* Radiation therapy (localized radiotherapy for analgesic purpose or for lytic lesions at risk of fracture) ≤2 weeks
